Hughes, D., Boyd, S., Giraldo, P., Gonzales, D., Holida, M., Goker-Alpan, O., … Chertkoff, R. (2020). Pegunigalsidase alfa, PEGylated α-galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal GB3 inclusion clearance and reduction of plasma Lyso-GB3. In Molecular Genetics and Metabolism (Vol. 129, pp. S76–S77). Elsevier BV. https://doi.org/10.1016/j.ymgme.2019.11.185

Hughes, Derralynn, Simeon Boyd, Pilar Giraldo, Derlis Gonzales, Myrl Holida, Ozlem Goker-Alpan, Mohamed G. Atta, et al. “Pegunigalsidase alfa, PEGylated α-galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal GB3 inclusion clearance and reduction of plasma Lyso-GB3.” In Molecular Genetics and Metabolism, 129:S76–77. Elsevier BV, 2020. https://doi.org/10.1016/j.ymgme.2019.11.185.

Hughes D, Boyd S, Giraldo P, Gonzales D, Holida M, Goker-Alpan O, et al. Pegunigalsidase alfa, PEGylated α-galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal GB3 inclusion clearance and reduction of plasma Lyso-GB3. In: Molecular Genetics and Metabolism. Elsevier BV; 2020. p. S76–7.

Hughes, Derralynn, et al. “Pegunigalsidase alfa, PEGylated α-galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal GB3 inclusion clearance and reduction of plasma Lyso-GB3.” Molecular Genetics and Metabolism, vol. 129, no. 2, Elsevier BV, 2020, pp. S76–77. Crossref, doi:10.1016/j.ymgme.2019.11.185.

Hughes D, Boyd S, Giraldo P, Gonzales D, Holida M, Goker-Alpan O, Atta MG, Nicholls K, Schiffmann R, Tuffaha A, Maegawa G, Barisoni L, Colvin R, Jennette JC, Alon S, Szlaifer M, Brill-Almon E, Chertkoff R. Pegunigalsidase alfa, PEGylated α-galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal GB3 inclusion clearance and reduction of plasma Lyso-GB3. Molecular Genetics and Metabolism. Elsevier BV; 2020. p. S76–S77.